Approval · Notice of Compliance 28705 · 2022
MAYZENT: Notice of Compliance 28705
Issued August 5, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 28705
- Date
- August 5, 2022
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Safety Update to the Product Monograph (PM) and Conversion to the 2020 Master Template.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MAYZENT | Not yet assigned | — |